Chronic hepatitis B affects 296 million people worldwide, with current treatments suppressing but never eliminating the virus that causes liver cancer and cirrhosis. The prospect of a functional cure—where patients maintain undetectable viral loads without lifelong medication—has remained elusive despite decades of research into this persistent infection. A breakthrough experimental approach demonstrates unprecedented success in achieving sustained viral suppression after treatment discontinuation. The investigational therapy targets hepatitis B surface antigen production and combines novel immunomodulatory agents with existing antiviral medications, resulting in functional cure rates exceeding 30% in early-phase clinical trials. Participants maintained undetectable viral DNA levels and normal liver enzymes for extended follow-up periods after stopping all medications. This represents a dramatic improvement over current standard-of-care treatments, which require indefinite daily medication and achieve functional cure in less than 5% of patients. The therapeutic strategy appears particularly effective in patients with lower baseline surface antigen levels, suggesting potential for personalized treatment protocols. While these results mark the most promising advancement in hepatitis B therapeutics in decades, several critical limitations remain. The study population was relatively small and homogeneous, and longer follow-up is essential to confirm durability of viral suppression. Additionally, the complex multi-drug regimen raises questions about tolerability and cost in real-world settings. The mechanism underlying sustained immune control after treatment cessation requires further elucidation. Nevertheless, this approach represents a paradigm shift from viral suppression to potential viral elimination, offering genuine hope for the hundreds of millions living with chronic hepatitis B infection.